Trial reportPediatric nephrology (Berlin, Germany)2009
Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome: a randomized prospective pilot trial.
Trial report in Pediatric nephrology (Berlin, Germany), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03776851 (Effect of Erythropoietin on Red Blood Cell Requirement in Children With Hemolytic Uremic Syndrome), which is not on this map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Erythropoietin on Red Blood Cell Requirement in Children With Hemolytic Uremic Syndrome: a Randomized Controlled Trial
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome.The Cochrane database of systematic reviews · 2025Pooled it
- Erythropoiesis-stimulating agents for preventing acute kidney injury.The Cochrane database of systematic reviews · 2024Pooled it
- Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome.The Cochrane database of systematic reviews · 2021Pooled it
- Guidelines for the management and investigation of hemolytic uremic syndrome.Clinical and experimental nephrology · 2014Guideline
- Erythropoietin in children with hemolytic uremic syndrome: a pilot randomized controlled trial.Pediatric nephrology (Berlin, Germany) · 2022Trial
- Erythropoietin in Acute Kidney Injury (EAKI): a pragmatic randomized clinical trial.BMC nephrology · 2022Trial
- How We Interpret Thrombosis with Thrombocytopenia Syndrome?International journal of molecular sciences · 2024Review
- Diagnosis and Treatment for Shiga Toxin-ProducingToxins · 2022Review
- Targeting the innate repair receptor axisFrontiers in immunology · 2022Article
- Review
- Review
- Recombinant Human Erythropoietin Therapy for a Jehovah's Witness Child With Severe Anemia due to Hemolytic-Uremic Syndrome.Korean journal of pediatrics · 2016Article
- Relationship between red blood cell transfusion requirements and severity of renal disease during the acute stage of hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2015Article
- [Advances in differential diagnosis and treatment of thrombotic microangiopathy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- Early erythropoietin in post-diarrheal hemolytic uremic syndrome: a case-control study.Pediatric nephrology (Berlin, Germany) · 2015Article
- Management of hemolytic-uremic syndrome in children.International journal of nephrology and renovascular disease · 2014Review
- Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide.Pediatric nephrology (Berlin, Germany) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood hemolytic uremic syndrome (HUS) is most often caused by enterohemorrhagic Escherichia coli (EHEC). Due to severe hemolysis, red blood cell (RBC) transfusions are often necessary, and anemia is aggravated by low erythropoietin (EPO) levels caused by acute renal failure. In a single center, prospective study, we randomized ten children with EHEC-positive HUS into two therapeutic groups: one receiving EPO treatment (median age 2 years, age range 1-3 years) and the other receiving standard therapy (median age 2 years, age range 1-6 years). Red blood cell transfusions were performed when the hemoglobin level (Hb) fell below 5 mg/dl. The number of RBC transfusions was compared in both groups. The Hb level at admission was comparable between both groups (6.4 vs. 8.1 mg/dl, P > 0.05, t-test). However, children in the EPO group required a significantly lower mean number of RBCs than those in the non-EPO group (0.2 vs. 1.4, P < 0.04, t-test). Based on these results, we suggest that the early administration of EPO at the time of hemolytic anemia and beginning renal failure may attenuate renal anemia in children with EHEC-induced HUS and thereby reduce the number of RBC transfusions required. The results of this pilot study will have to be confirmed in a larger multicenter trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.